GLPwatch
Papers (10409)
Page 108 of 174, ranked by citation count.
- GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis.
- Prepregnancy GLP-1RA use improves maternal lipid metabolism via liver-secreted FGF21 during pregnancy in HFD-fed dams.
- Systemic semaglutide provides a mild vasoprotective and antineuroinflammatory effect in a rat model of ocular hypertensive glaucoma.
- Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.
- Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats.
- Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
- A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic.
- Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.
- Tirzepatide-Associated Colonic Ischemia.
- The Modified Exenatide Microspheres: PLGA-PEG-PLGA Gel and Zinc-Exenatide Complex Synergistically Reduce Burst Release and Shorten Platform Stage.
- [GLP-1 analogues in treatment of type 1 diabetes mellitus].
- Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
- Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
- Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients.
- Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.
- Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity.
- Tirzepatide decreases systolic and diastolic blood pressure.
- Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.
- Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.
- A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.
- Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
- Exenatide-Induced Panniculitis: Utility of the Acid-Fast Stain to Identify Injected Microspheres.
- Lixisenatide ameliorated lipopolysaccharide (LPS)-induced expression of mucin and inflammation in bronchial epithelial cells.
- The need to personalise approaches for the prevention and management of obesity.
- The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
- Effects of glucagon-like peptide-1 receptor agonists on spermatogenesis-related gene expression in mouse testis and testis-derived cell lines.
- Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.
- Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
- GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.
- Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide "a glucagon-like peptide-1 analogue" via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways.
- Liraglutide improves cognition function in streptozotocin-induced diabetic rats by downregulating β-secretase and γ-secretase and alleviating oxidative stress in HT-22 cells.
- Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3/NF-κB signaling pathway.
- Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model.
- An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review.
- Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.
- Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.
- Exacerbation of atrial fibrillation related to dulaglutide use.
- Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR).
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Enhancing Stability of Exenatide-Containing Pressurized Metered-Dose Inhaler Via Reverse Microemulsion System.
- Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies.
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.
- Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats.
- Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.
- Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
- Greater Combined Reductions of HbA<sub>1c</sub> ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.
- G protein-coupled receptors and obesity.
- Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.
- Treatment evaluation of liraglutide in type 2 diabetes.
- Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
- Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
- Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.
- Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
- Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes.
- Liraglutide chronic treatment prevents development of tolerance to antiseizure effects of diazepam in genetically epilepsy prone rats.
- Novel ABCA1 peptide agonists with antidiabetic action.
- Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.
- Semaglutide in NASH-related cirrhosis: too late to the party?